Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Greater Health Information Exchange In Next Phase Of HIT Meaningful Use

Executive Summary

More stringent requirements for health information exchange, as well as clinical decision support, will be a part of the next phase of requirements to demonstrate the meaningful use of health information technology, HHS' David Blumenthal said.

You may also be interested in...



EHR “Meaningful Use” Requirements Raise Expectations For Health Information Exchange In Stage 2

CMS highlights the greater role that health information exchange will play in stage 2 meaningful use for electronic health records and sets the stage for an even more robust use of health data to promote safety and efficiency as the agency moves toward stage 3.

More Robust Health Information Exchange Needed To Boost Health IT Utilization – Bipartisan Policy Center

Getting the most out of the movement towards the use of electronic health records will depend on how well data are exchanged. The Bipartisan Policy Center offers recommendations on building a better environment for exchanging information.

EHR Meaningful Use Could See Optional Items Become Requirements In Stage 2

Preliminary objectives of next round of demonstrating meaningful use of electronic health records also include greater emphasis on clinical decision support and health information exchange, as expected.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel